AKEBIA THERAPEUTICS, INC. Reimbursement Revenue (Deprecated 2018-01-31)
AKEBIA THERAPEUTICS, INC. (AKBA) reported Reimbursement Revenue (Deprecated 2018-01-31) of $64.00 thousand for the 3-month period ending 2015-09-30, per its 10-Q filed 2015-11-09.
Discontinued › Income Statement › Other Income
us-gaap:ReimbursementRevenue · last filed 2015-11-09
- AKEBIA THERAPEUTICS, INC. reimbursement revenue (deprecated 2018-01-31) for the quarter ending 2015-09-30 was $64.00K, a 64.44% decline year-over-year.
- AKEBIA THERAPEUTICS, INC. reimbursement revenue (deprecated 2018-01-31) for the quarter ending 2015-06-30 was $84.00K, a 50.88% decline year-over-year.
- AKEBIA THERAPEUTICS, INC. reimbursement revenue (deprecated 2018-01-31) for the quarter ending 2015-03-31 was $105.00K, a 45.60% decline year-over-year.
- AKEBIA THERAPEUTICS, INC. reimbursement revenue (deprecated 2018-01-31) for the quarter ending 2014-12-31 was $156.23K, a 33.19% decline year-over-year.
- AKEBIA THERAPEUTICS, INC. reimbursement revenue (deprecated 2018-01-31) for fiscal 2014 was $700.23K, a 33.30% decline from fiscal 2013.
- AKEBIA THERAPEUTICS, INC. reimbursement revenue (deprecated 2018-01-31) for fiscal 2013 was $1.05M, a 46.74% decline from fiscal 2012.
- AKEBIA THERAPEUTICS, INC. reimbursement revenue (deprecated 2018-01-31) for fiscal 2012 was $1.97M.
| Period end | Reimbursement Revenue (Deprecated 2018-01-31) 3 month | Reimbursement Revenue (Deprecated 2018-01-31) 3 month as first filed | Reimbursement Revenue (Deprecated 2018-01-31) 6 month | Reimbursement Revenue (Deprecated 2018-01-31) 6 month as first filed | Reimbursement Revenue (Deprecated 2018-01-31) 9 month | Reimbursement Revenue (Deprecated 2018-01-31) 12 month | Reimbursement Revenue (Deprecated 2018-01-31) 85 month |
|---|---|---|---|---|---|---|---|
| 2015-09-30 | $64.00K 10-Q · filed 2015-11-09 | $148.00K derived: sum of 2 quarters · filed 2015-11-09 | $254.00K 10-Q · filed 2015-11-09 | $409.23K derived: sum of 4 quarters · filed 2015-11-09 | |||
| 2015-06-30 | $84.00K 10-Q · filed 2015-08-11 | $189.00K 10-Q · filed 2015-08-11 | $345.23K derived: sum of 3 quarters · filed 2015-08-11 | $525.23K derived: sum of 4 quarters · filed 2015-11-09 | |||
| 2015-03-31 | $105.00K 10-Q · filed 2015-05-11 | $261.23K derived: sum of 2 quarters · filed 2015-05-11 | $441.23K derived: sum of 3 quarters · filed 2015-11-09 | $612.23K derived: sum of 4 quarters · filed 2015-11-09 | |||
| 2014-12-31 | $156.23K derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-04 | $336.23K derived: sum of 2 quarters · filed 2015-11-09 | $507.23K derived: sum of 3 quarters · filed 2015-11-09 | $700.23K 10-K · filed 2015-03-04 | |||
| 2014-09-30 | $180.00K 10-Q · filed 2015-11-09 | $351.00K derived: sum of 2 quarters · filed 2015-11-09 | $544.00K 10-Q · filed 2015-11-09 | $777.84K derived: sum of 4 quarters · filed 2015-11-09 | |||
| 2014-06-30 | $171.00K 10-Q · filed 2015-08-11 | $171.23K 10-Q · filed 2014-08-11 | $364.00K 10-Q · filed 2015-08-11 | $364.34K 10-Q · filed 2014-08-11 | $597.84K derived: sum of 3 quarters · filed 2015-08-11 | $835.84K derived: sum of 4 quarters · filed 2015-08-11 | |
| 2014-03-31 | $193.00K 10-Q · filed 2015-05-11 | $193.11K 10-Q · filed 2014-05-12 | $426.84K derived: sum of 2 quarters · filed 2015-05-11 | $664.84K derived: sum of 3 quarters · filed 2015-05-11 | $952.29K derived: sum of 4 quarters · filed 2015-05-11 | $3.21M 10-Q · filed 2014-05-12 | |
| 2013-12-31 | $233.84K derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-04 | $471.84K derived: sum of 2 quarters · filed 2015-03-04 | $759.29K derived: sum of 3 quarters · filed 2015-03-04 | $1.05M 10-K · filed 2015-03-04 | |||
| 2013-09-30 | $238.00K 10-Q · filed 2014-11-10 | $525.45K derived: sum of 2 quarters · filed 2014-11-10 | $816.00K 10-Q · filed 2014-11-10 | ||||
| 2013-06-30 | $287.44K 10-Q · filed 2014-08-11 | $577.60K 10-Q · filed 2014-08-11 | |||||
| 2013-03-31 | $290.15K 10-Q · filed 2014-05-12 | ||||||
| 2012-12-31 | $1.97M 10-K · filed 2015-03-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |